TITLE

Risperdal Consta update

PUB. DATE
November 2009
SOURCE
MPR - Residents' Edition;Fall/Winter2009, Vol. 18 Issue 2, pA7
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the approval of the new monotherapy or adjuvant therapy Risperdal Consta from Janssen Pharmaceutica NV in the maintenance treatment of bipolar I disorder by the U.S. Food and Drug Administration (FDA). It mentions that the drug is a risperidone long-acting injection and it is used as adjuvant therapy to lithium and valproate. It also states that the drug can also be indicated to patients with schizophrenia.
ACCESSION #
44921147

 

Related Articles

  • First antipsychotic medication endorsed for children and teens.  // Contemporary Pediatrics;Sep2007, Vol. 24 Issue 9, p23 

    The article reports on the approval of risperidone by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adolescents ages 13 to 17 on August 22, 2007. The drug can also be used as a short-term treatment of manic or mixed episodes of bipolar I disorder in children...

  • Quetiapine.  // AHFS Consumer Medication Information;Feb2020, p1 

    Quetiapine tablets and extended-release (long-acting) tablets are used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Quetiapine tablets and extended-release tablets are also...

  • J&J Files NDA for New Formulation for Risperdal. Krause, Caret // Chemical Market Reporter;9/10/2001, Vol. 260 Issue 10, p9 

    Reports on a drug application filed by Johnson & Johnson's Janssen Pharmaceutical Products LP with the United States Food and Drug Administration for a long-acting injectable formulation of Risperdal. Dosage for long-acting Risperdal; Advantage of long-acting Risperdal over Zyprexa atypical...

  • NEW DOSING OPTIONS.  // Drug Topics;5/8/2006, Vol. 150 Issue 9, p53 

    The article introduces two additional dosages for Janssen Pharmaceutica NV's Risperdal M-Tablets, the fast-dissolving form of the antipsychotic medication risperidone. Risperdal is indicated for the treatment of schizophrenia and for the short-term treatment of bipolar mania.

  • Neurology.  // PharmaWatch: CNS;January 2004, Vol. 3 Issue 1, p4 

    Reports on Janssen Pharmaceutica NV's launch of Risperdal Consta injectable respiridone in the United States. Intramuscular injection of the drug; Estimated number of Americans suffering from schizophrenia; Food and Drug Administration's approval of the drug in 2003.

  • FDA Issues CRL for Alexza Pharmaceuticals' Adasuve. Shaffer, Catherine // BioWorld Today;5/7/2012, Vol. 23 Issue 88, p1 

    This article reports on the decision of the U.S. Food and Drug Administration (FDA) to issue a complete response letter for Alexza Pharmaceuticals Inc.'s Adasuve inhalation powder for agitation in schizophrenia and bipolar disorder. According to the company, the agency cited manufacturing...

  • FDA Actions. Elliott, William T. // Clinical Cardiology Alert;Nov2009 Pharmacology Watch, p2 

    This section offers news briefs concerning the Food and Drug Administration (FDA) in the U.S. Asenapine has been given approval by the FDA as cure for schizophrenia and bipolar I disorder in adults. The FDA also reduced the approved age limit for levocetirizine to 6 months for children suffering...

  • FDA Actions. Elliott, William T. // Primary Care Reports;Nov2009 Pharmacology Watch, p2 

    The article presents updates about the drug approval decisions of the U.S. Food and Drug Administration (FDA). Asenaphine has been approved for treating schizophrenia and bipolar I disorder in adults. This is expected to carry a warning regarding increased mortality in elderly patients with...

  • FDA Actions. Elliott, William T. // Clinical Oncology Alert;Nov2009 Supplement, p2 

    This section offers news briefs concerning the Food and Drug Administration (FDA) in the U.S. Asenapine has been given approval by the FDA as cure for schizophrenia and bipolar I disorder in adults. The FDA also reduced the approved age limit for levocetirizine to 6 months for children suffering...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics